Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine-midazolam versus ketamine-dexmedetomidine sedation in uncooperative children undergoing dental treatment
IRCT20230629058616N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine, midazolam and dexmedetomidine in anxiety disorder (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Success of dental treatment according to the Houpt criterion. Started Aug 2023; status: completed.
02
Drugs
ketaminemidazolamdexmedetomidine
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on IRCT20230629058616N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230629058616N1.